Individuals were prospectively divided into three tumor HRD subgroups: (germline or somatic), wild type (and low LOH (LOHlow) utilizing the Foundation Medicine T5 next-generation sequencing assay

Individuals were prospectively divided into three tumor HRD subgroups: (germline or somatic), wild type (and low LOH (LOHlow) utilizing the Foundation Medicine T5 next-generation sequencing assay. inhibition leads to synthetic lethality and tumor PPIA cell death.4 Additional pathways for synthetic lethality via PARP inhibition include trapping the PARP-1 enzyme on damaged DNA, effectively preventing continuation…